Literature DB >> 14752006

Guidelines for hypertension: are quality-assurance measures on target?

Gregory M Singer1, Munavvar Izhar, Henry R Black.   

Abstract

Guideline committees recommend targets of treatment based on trial data on efficacy and effectiveness. Quality-assurance initiatives apply these parameters in the general practice setting. Therefore, targets must be feasible and achievable by the practicing physicians who are judged by these targets as goals for care. We evaluated 437 patients in the Rush University Hypertension Clinic using the Health Employer Data Information Set (HEDIS) measures for 2000 to assess goal achievement in a practice-based setting. We compared guideline achievement of uncomplicated hypertensive and diabetic subjects to standards dictated by HEDIS, the 6th Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI), and the American Diabetic Association (ADA)/National Kidney Foundation (NKF). Overall, 276 (63%) patients achieved SBP goal, with 376 (86%) achieving DBP goal and 358 (59%) achieving both goals. However, in the 20% of patients who were diabetic, only 52% had a BP of <140 mm Hg and <90 mm Hg, whereas only 22% achieved the more stringent goals of JNC VI of <130 mm Hg systolic and <85 mm Hg diastolic and only 15% achieved the ADA/NKF goals of <130 mm Hg systolic and <80 mm Hg diastolic. Although goal was achievable in most uncomplicated hypertension, hypertension in diabetes was more difficult to control, despite being more likely to receive enhanced benefit from effective management. Goal-oriented strategy, especially in diabetic subjects, should be aggressively sought rather than relaxing goals to promote achievement.

Entities:  

Mesh:

Year:  2004        PMID: 14752006     DOI: 10.1161/01.HYP.0000114697.14697.d2

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  9 in total

1.  Hypertension improvement project: randomized trial of quality improvement for physicians and lifestyle modification for patients.

Authors:  Laura P Svetkey; Kathryn I Pollak; William S Yancy; Rowena J Dolor; Bryan C Batch; Greg Samsa; David B Matchar; Pao-Hwa Lin
Journal:  Hypertension       Date:  2009-12       Impact factor: 10.190

2.  Actions to control high blood pressure among hypertensive adults in Texas counties along the Mexico border: Texas BRFSS, 2007.

Authors:  Carma Ayala; Jing Fang; Luis Escobedo; Stephen Pan; Hector G Balcazar; Guijing Wang; Robert Merritt
Journal:  Public Health Rep       Date:  2012 Mar-Apr       Impact factor: 2.792

Review 3.  Treatment and blood pressure control in 47,964 people with diabetes and hypertension: a systematic review of observational studies.

Authors:  Donna L McLean; Scot H Simpson; Finlay A McAlister; Ross T Tsuyuki
Journal:  Can J Cardiol       Date:  2006-08       Impact factor: 5.223

Review 4.  Management of hypertension and diabetes: treatment goals, drug choices, current practice, and strategies for improving care.

Authors:  Ann M Borzecki; Dan R Berlowitz
Journal:  Curr Hypertens Rep       Date:  2005-12       Impact factor: 5.369

5.  Amlodipine added to quinapril vs quinapril alone for the treatment of hypertension in diabetes: the Amlodipine in Diabetes (ANDI) trial.

Authors:  Sheldon Tobe; Kalina Kawecka-Jaszcz; Faiez Zannad; George Vetrovec; Rajiv Patni; Harry Shi
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-02       Impact factor: 3.738

Review 6.  Services aimed at achieving desirable clinical outcomes in patients with chronic kidney disease and diabetes mellitus: A narrative review.

Authors:  Fergus William Gardiner; Ezekiel Uba Nwose; Phillip Taderera Bwititi; Judith Crockett; Lexin Wang
Journal:  SAGE Open Med       Date:  2017-11-17

7.  Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study.

Authors:  Henry R Black; George L Bakris; Michael A Weber; Robert Weiss; Mahfouz El Shahawy; Richard Marple; Georges Tannoury; Stuart Linas; Brian L Wiens; Jennifer V Linseman; Robert Roden; Michael J Gerber
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-10       Impact factor: 3.738

8.  Ethnic differences in the treatment and control of hypertension in patients with diabetes.

Authors:  Jessica Flynn Riehle; Daniel T Lackland; Eni C Okonofua; Katherine H Hendrix; Brent M Egan
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-08       Impact factor: 3.738

9.  Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes.

Authors:  James R Sowers; Joel M Neutel; Elijah Saunders; George L Bakris; William C Cushman; Keith C Ferdinand; Elizabeth O Ofili; Michael A Weber
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-07       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.